The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)

Data publikacji: 14 paź 2021

Zakres stron: 157 - 161

Otrzymano: 04 wrz 2021

Przyjęty: 11 wrz 2021

DOI: https://doi.org/10.2478/jim-2021-0030

Słowa kluczowe

monoclonal antibody therapy, severe eosinophilic asthma, clinical parameters, eosinophils

© 2021 Nimród László et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.